According to a New York Times article, "With a steep drop in the costs of sequencing and an explosion of research on genes, medical experts expect that genetic analyses of cancers will become routine. Just as pathologists do blood cultures to decide which antibiotics will stop a patient’s bacterial infection, so will genome sequencing determine which drugs might stop a cancer."
To read the entire article, click here. For more information on the topic, read the NYTimes feature, "A New Treatment’s Tantalizing Promise Brings Heartbreaking Ups and Downs."
